KRTL Holding Group (OTC: KRTL) Boosts Pharma Import Readiness and Regulatory Compliance
Considering the fact that KRTL Holding Group (OTC: KRTL) made an announcement with regards to a key business milestone yesterday, it is likely that the stock may be in focus today. The company announced that it had set up an advanced QMS (Quality Management System) named MasterControl to significantly enhance its operations.
Key Details
The company noted that the implementation had been done at KRTL Biotech Inc., its fully owned subsidiary unit. As a consequence of the move, the regulatory framework in relation to KRTL Biotech would be considerably enhanced, making operations more efficient and ensuring that the import of pharmaceuticals takes place in compliance with worldwide standards.
Further Information
In the news release, it was further noted that the implementation of the new QMS was another demonstration of KRTL Biotech’s steadfast commitment to the maintenance of the highest standards of regulatory frameworks at a federal and global level. Additionally, the move would also enable the subsidiary to adhere to the framework related to the GMP (Good Manufacturing Practices). It is going to be interesting to see if the KRTL Holding Group stock gets any attention from investors this week or not.
CEO Quote
“By adopting MasterControl, KRTL Biotech is future-proofing its compliance infrastructure and positioning itself as a key player in pharmaceutical importation, biotechnological innovation, and corporate expansion,” stated Cesar Herrera, CEO of KRTL Holding Group Inc.
Fundamentals
| P/E Ratio | 32.5000 |
| PEG Ratio | – |
| Price to Book | 7.59 |
| Price to Cash Flow | 148.166 |
| Price to Free Cash Flow | 148.166 |
| Total Sales (TTM) | 2.64 M |
| Revenue per Share (TTM) | 0.01 |
| Shares Outstanding | 71.666 M |
| Share Float (%) | – |
